SUBSCRIBE
SUBSCRIBE

Longboard Pharmaceuticals

NEWS
Pictured: Bar and line graphs showing increasing t
Drug Development
Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering
Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.
January 3, 2024
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
Drug Development
Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
August 23, 2023
 · 
8 min read
Business
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 3, 2023
 · 
9 min read
Biotech Beach
Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
August 3, 2023
 · 
2 min read
Biotech Beach
Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023
June 26, 2023
 · 
2 min read
Business
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 9, 2023
 · 
9 min read
Biotech Beach
Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
 · 
2 min read
BioMidwest
Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352
April 5, 2023
 · 
5 min read
Business
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives
March 2, 2023
 · 
13 min read
Biotech Beach
Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
February 10, 2023
 · 
2 min read
Biotech Beach
Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 7, 2023
 · 
4 min read
Load More
JOBS